Table 2.
MBL-2 Genotypes in Cases of Cryptococcal Meningitis, Immunocompetent Patients, and Healthy Control
| Genotype | Cryptococcal meningitis |
Control subjects (n = 208) (%) | |||||
| Overall (n = 103) (%) | OR (95% CI) a | P a | Immunocompetent patients (n = 52) (%) | OR (95% CI) b | P b | ||
| Coding genotypec | |||||||
| A/A | 67 (65.1) | 0.75 (.44–1.29) | .273 | 34 (65.4) | 0.77 (.39–1.56) | .417 | 148 (71.2) |
| A/Oc | 28 (27.2) | 1.01 (.51–1.77) | .961 | 12 (23.1) | 0.81 (.36–1.73) | .572 | 56 (26.9) |
| O/O | 8 (7.8) | 4.29 (1.11–19.88) | .023 | 6 (11.5) | 6.65 (1.49–33.05) | .005 | 4 (1.9) |
| Genotype groupd | |||||||
| high | 65 (63.1) | 0.76 (.45–1.29) | .279 | 34 (65.4) | 0.82 (.42–1.66) | .544 | 144 (69.2) |
| low | 21 (20.4) | 0.90 (.48–1.66) | .727 | 8 (15.4) | 0.64 (.24–1.51) | .285 | 46 (22.1) |
| deficient | 17 (16.5) | 2.09 (.96–4.51) | .039 | 10 (19.2) | 2.51 (.96–6.22) | .028 | 18 (8.7) |
NOTE. aOverall cases of cryptococcal meningitis vs healthy control subjects.
b
Immunocompetent patients vs healthy control subjects.
c
A/O including A/B, A/D; O/O including B/B, B/D.
d
High including HYPA/HYPA, HYPA/LYQA, HYPA/LYPA, HYPA/LXPA, LYQA/LYQA, LYQA/LYPA, LYQA/LXPA, LYPA/LYPA, LYPA/LXPA; low including LXPA/LXPA, HYPA/LYPB, LYQA/LYPB, LYPA/LYPB, HYPA/HYPD, LYQA/HYPD; deficient including LXPA/LYPB, LYPB/LYPB, LYPB/HYPD.